CD47 as a promising therapeutic target in oncology
CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipu...
Main Authors: | Hai Zhao, Shuangshuang Song, Junwei Ma, Zhiyong Yan, Hongwei Xie, Ying Feng, Shusheng Che |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.757480/full |
Similar Items
-
The role of CD47 in non-neoplastic diseases
by: Chao Wang, et al.
Published: (2023-12-01) -
Targeting CD47 as a therapeutic strategy: A common bridge in the therapy of COVID-19-related cancers
by: Milad Zandi, et al.
Published: (2023-07-01) -
Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade
by: Abdullahi Alausa, et al.
Published: (2022-07-01) -
Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
by: Haiqin Liao, et al.
Published: (2022-04-01) -
CD47–SIRPα-targeted therapeutics: status and prospects
by: R. Maute, et al.
Published: (2022-03-01)